Epizyme was founded in 2007 and is headquartered in Cambridge, US

Executive Vice President and Chief Scientific Officer

Epizyme has an office in Cambridge

Cambridge, US (HQ)

400 Technology Square

Epizyme's revenue was reported to be $8 m in FY, 2016

USD

## Net income (Q1, 2017) | (32.5 m) |

## EBIT (Q1, 2017) | (33 m) |

## Market capitalization (18-Aug-2017) | 820.2 m |

## Cash (31-Mar-2017) | 64.4 m |

Epizyme's current market capitalization is $820.2 m.

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Revenue | 68.5 m | 41.4 m | 2.6 m | 8 m |

## Revenue growth, % | (40%) | (94%) | 213% | |

## R&D expense | 91.5 m | |||

## General and administrative expense | 28.4 m | |||

## Operating expense total | 71.6 m | 96.5 m | 135.1 m | 119.8 m |

## EBIT | (3.1 m) | (55.1 m) | (132.5 m) | (111.8 m) |

## EBIT margin, % | (5%) | (133%) | (5178%) | (1397%) |

## Interest income | 74 k | 95 k | ||

## Pre tax profit | (3.1 m) | (54.9 m) | (132.4 m) | (110.2 m) |

## Income tax expense | 349 k | 109 k | ||

## Net Income | (3.5 m) | (55 m) | (132.4 m) | (110.2 m) |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## R&D expense | 17.5 m | 22.2 m | 57.1 m | 20.6 m | 16.8 m | 17.7 m | 21.5 m | 23.9 m | 24.7 m |

## General and administrative expense | 5.3 m | 5.7 m | 5.2 m | 6 m | 6.7 m | 5.8 m | 7.4 m | 7.5 m | 8.3 m |

## Operating expense total | 22.8 m | 27.9 m | 62.3 m | 26.5 m | 23.5 m | 23.6 m | 28.9 m | 31.4 m | 33 m |

## EBIT | (13.3 m) | (19.7 m) | (61.4 m) | (25.8 m) | (23.1 m) | (23.1 m) | (28.4 m) | (24.8 m) | (33 m) |

## Interest income | 26 k | 24 k | 31 k | ||||||

## Pre tax profit | (13.3 m) | (19.7 m) | (25.8 m) | (23.1 m) | |||||

## Income tax expense | 113 k | 5 k | 113 k | 5 k | |||||

## Net Income | (20.3 m) | (40 m) | (61.3 m) | (25.8 m) | (23.1 m) | (22.9 m) | (28 m) | (24.3 m) | (32.5 m) |

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Cash | 123.6 m | 190.1 m | 208.3 m | 77.9 m |

## Accounts Receivable | 33.7 m | 2.1 m | 262 k | 23 k |

## Inventories | 2.4 m | 2.8 m | 4.5 m | 6.5 m |

## Current Assets | 159.7 m | 195 m | 213.1 m | 248.7 m |

## PP&E | 2.2 m | 3.6 m | 4.1 m | 3.1 m |

## Total Assets | 163 m | 199.2 m | 217.9 m | 252.4 m |

## Accounts Payable | 4.7 m | 8.3 m | 4.7 m | 5 m |

## Current Liabilities | 34.6 m | 17 m | 18.4 m | 21.6 m |

## Additional Paid-in Capital | 160.4 m | 271.4 m | 413 m | 555.5 m |

## Retained Earnings | (56.1 m) | (111.1 m) | (243.5 m) | (353.7 m) |

## Total Equity | 104.3 m | 160.3 m | 169.5 m | 201.7 m |

## Financial Leverage | 1.6 x | 1.2 x | 1.3 x | 1.3 x |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Cash | 229.9 m | 211.7 m | 244.5 m | 236.7 m | 229.9 m | 312.7 m | 89.5 m | 66 m | 64.4 m |

## Accounts Receivable | 2.2 m | 2.1 m | 365 k | 723 k | 177 k | 176 k | 60 k | 6.2 m | 8 k |

## Current Assets | 234.7 m | 217.1 m | 247.4 m | 239.4 m | 232.6 m | 318.3 m | 296.6 m | 275 m | 220 m |

## PP&E | 2.6 m | 2.7 m | 5.2 m | 4.9 m | 4.5 m | 3.8 m | 3.6 m | 3.3 m | 3.3 m |

## Total Assets | 238.4 m | 220.8 m | 253.3 m | 245 m | 237.7 m | 322.7 m | 300.9 m | 279 m | 223.9 m |

## Accounts Payable | 4.5 m | 5.7 m | 5.1 m | 3 m | 3 m | 2.2 m | 3.7 m | 3.4 m | 7.3 m |

## Current Liabilities | 23.8 m | 23.8 m | 11.9 m | 13.2 m | 17.5 m | 14 m | 16.2 m | 15.9 m | 20.5 m |

## Additional Paid-in Capital | 266 m | 268.8 m | 390.8 m | 407.1 m | 410.8 m | 545.3 m | 549.5 m | 552.5 m | 560.9 m |

## Retained Earnings | (76.4 m) | (96.1 m) | (172.4 m) | (198.2 m) | (221.2 m) | (266.3 m) | (294.3 m) | (318.7 m) | (386.3 m) |

## Total Equity | 189.6 m | 172.8 m | 218.4 m | 208.9 m | 189.6 m | 279 m | 255.2 m | 233.8 m | 174.5 m |

## Financial Leverage | 1.3 x | 1.3 x | 1.2 x | 1.2 x | 1.3 x | 1.2 x | 1.2 x | 1.2 x | 1.3 x |

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Net Income | (3.5 m) | (55 m) | (132.4 m) | (110.2 m) |

## Depreciation and Amortization | 703 k | 742 k | 1.4 m | 1.6 m |

## Accounts Receivable | (32 m) | 31.6 m | 1.8 m | 239 k |

## Inventories | (1.5 m) | (419 k) | (1.6 m) | (1.5 m) |

## Accounts Payable | 1.6 m | 3.6 m | (3.6 m) | 341 k |

## Cash From Operating Activities | (53.7 m) | (35.4 m) | (72.9 m) | (96.4 m) |

## Purchases of PP&E | (630 k) | (2.2 m) | (183 k) | (624 k) |

## Cash From Investing Activities | (630 k) | (2.2 m) | (40.2 m) | (165.4 m) |

## Cash From Financing Activities | 79.9 m | 104.1 m | 131.3 m | 131.4 m |

## Income Taxes Paid | 963 k | 963 k | 963 k |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Net Income | (20.3 m) | (40 m) | (61.3 m) | (25.8 m) | (23.1 m) | (22.9 m) | (28 m) | (24.3 m) | (32.5 m) |

## Depreciation and Amortization | 362 k | 548 k | 260 k | 389 k | |||||

## Accounts Receivable | 31.5 m | 31.6 m | 1.7 m | 723 k | 177 k | 86 k | 60 k | 6.2 m | 8 k |

## Accounts Payable | (142 k) | 1.1 m | (3.2 m) | 3 m | 3 m | (2.4 m) | 3.7 m | 3.4 m | 7.3 m |

## Cash From Operating Activities | 4.7 m | (14.4 m) | (22.7 m) | (25.4 m) | |||||

## Purchases of PP&E | (824 k) | (1.2 m) | (163 k) | (70 k) | |||||

## Cash From Investing Activities | (824 k) | (1.2 m) | (40.2 m) | (70 k) | |||||

## Cash From Financing Activities | 102.5 m | 103.7 m | 117.3 m | 129.8 m | |||||

## Income Taxes Paid | 2 k |

Y, 2017 | |
---|---|

## Financial Leverage | 1.3 x |